Optic neuritis and risk of MS: Differential diagnosis and management

Cleveland Clinic Journal of Medicine

Volumn 76, Issue 3, 2009, Pages 181-190

  Osborne, Benjamin J ^a   Volpe, Nicholas J ^b  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; GLUCOCORTICOID; IMMUNOLOGIC FACTOR;

DIFFERENTIAL DIAGNOSIS; HUMAN; MULTIPLE SCLEROSIS; OPTIC NEURITIS; PROGNOSIS; REVIEW; VISUAL SYSTEM EXAMINATION;

DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC TECHNIQUES, OPHTHALMOLOGICAL; GLUCOCORTICOIDS; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; MULTIPLE SCLEROSIS; OPTIC NEURITIS; PROGNOSIS;

EID: 66149086579     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.76a.07268     Document Type: Review

References (59)

1. Liu GT. Visual loss: optic neuropathies. In: Liu GT, Volpe NJ, Galetta SL, editors. Neuro-Ophthalmology: Diagnosis and Management. Philadelphia, PA: WB Saunders, 2001:103-187.
2. Wray SH. Optic neuritis. In: Albert DM, Jakobiec FA, editors. Principles and Practice of Ophthalmology. Philadelphia, PA: WB Saunders, 1994:2539-2568.
3. Optic Neuritis Study Group. The clinical profile of optic neuritis: experience of the Optic Neuritis Treatment Trial. Arch Ophthalmol 1991; 109:1673-1678.
4. Percy AK, Nobrega FT, Kurland LT. Optic neuritis and multiple sclerosis: an epidemiologic study. Arch Ophthalmol 1972; 87:135-139.
5. Rodriguez M, Siva A, Cross SA, O'Brien PC, Kurland LT. Optic neuritis: a population-based study in Olmsted County, Minnesota. Neurology 1995; 45:244-250.
6. Phillips PH, Newman NJ, Lynn MJ. Optic neuritis in African Americans. Arch Neurol 1998; 55:186-192.
7. Brady KM, Brar AS, Lee AG, Coats DK, Paysse EA, Steinkuller PG. Optic neuritis in children: clinical features and visual outcome. J AAPOS 1999; 3:98-103.
8. Kriss A, Francis DA, Cuendet B, et al. Recovery after optic neuritis in childhood. J Neurol Neurosurg Psychiatry 1988; 51:1253-1258.
9. Kennedy C, Carroll FD. Optic neuritis in children. Arch Ophthalmol 1960; 63:747-755.
10. Beck RW. The Optic Neuritis Treatment Trial. Arch Ophthalmol 1988; 106:1051-1053.
11. Optic Neuritis Study Group. Visual function 15 years after optic neuritis. Ophthalmology 2008; 115:1079-1082.
12. Cox TA, Thompson HS, Corbett JJ. Relative afferent pupillary defects in optic neuritis. Am J Ophthalmol 1981; 92:685-690.
13. Arnold AC. Ischemic optic neuropathies. Ophthalmol Clin North Am 2001; 14:83-98.
14. Newman NJ, Scherer R, Langenberg P, et al. The fellow eye in NAION: report from the ischemic optic neuropathy decompression trial follow-up study. Am J Ophthalmol 2002; 134:317-328.
15. Hayreh SS, Podhajsky PA, Zimmerman B. Ipsilateral recurrence of nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol 2001; 132:734-742.
16. Liozon E, Herrmann F, Ly K, et al. Risk factors for visual loss in giant cell (temporal) arteritis: a prospective study of 174 patients. Am J Med 2001; 111:211-217.
17. Buono LM, Foroozan R. Perioperative posterior ischemic optic neuropathy: review of the literature. Surv Ophthalmol 2005; 50:15-26.
18. American Society of Anesthesiologists Task Force on Perioperative Blindness. Practice advisory for perioperative visual loss associated with spine surgery: a report by the American Society of Anesthesiologists Task Force on Perioperative Blindness. Anesthesiology 2006; 104:1319-1328.
19. Merle H, Olindo S, Bonnan M, et al. Natural history of the visual impairment of relapsing neuromyelitis optica. Ophthalmology 2007; 114:810-815.
20. Papais-Alvarenga RM, Carellos SC, Alvarenga MP, Holander C, Bichara RP, Thuler LC. Clinical course of optic neuritis in patients with relapsing neuromyelitis optica. Arch Ophthalmol 2008; 126:12-16.
21. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999; 53:1107-1114.
22. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006; 66:1485-1489.
23. Takahashi T, Fujihara K, Nakashima I, et al. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain 2007; 130:1235-1243.
24. Sibony P, Halperin J, Coyle PK, Patel K. Reactive Lyme serology in optic neuritis. J Neuroophthalmol 2005; 25:71-82.
25. Anninger WV, Lomeo MD, Dingle J, Epstein AD, Lubow M. West Nile virus-associated optic neuritis and chorioretinitis. Am J Ophthalmol 2003; 136:1183-1185.
26. Jabs DA, Miller NR, Newman SA, Johnson MA, Stevens MB. Optic neuropathy in systemic lupus erythematosus. Arch Ophthalmol 1986; 104:564-568.
27. Howell N. LHON and other optic nerve atrophies: the mitochondrial connection. Dev Ophthalmol 2003; 37:94-108.
28. Newman NJ. Hereditary optic neuropathies. In: Miller NR, Newman NJ, editors. Walsh and Hoyt's Clinical Neuro-ophthalmology. Philadelphia, PA: Lippincott Williams & Wilkins, 2005; 465-501.
29. Smith JL, Hoyt WF, Susac JO. Ocular fundus in acute Leber optic neuropathy. Arch Ophthalmol 1973; 90:349-354.
30. Votruba M, Thiselton D, Bhattacharya SS. Optic disc morphology of patients with OPA1 autosomal dominant optic atrophy. Br J Ophthalmol 2003; 87:48-53.
31. Alexander C, Votruba M, Pesch UE, et al. OPA1, encoding a dynaminrelated GTPase, is mutated in autosomal dominant atrophy linked to chromosome 3q28. Nat Genet 2000; 26:211-215.
32. McKinley SH, Foroozan R. Optic neuropathy associated with linezolid treatment. J Neuroophthalmol 2005; 25:18-21.
33. Melamud A, Kosmorsky GS, Lee MS. Ocular ethambutol toxicity. Mayo Clin Proc 2003; 78:1409-1411.
34. Kerrison JB. Optic neuropathies caused by toxins and adverse drug reactions. Ophthalmol Clin North Am 2004; 17:481-488.
35. Pomeranz HD, Bhavsar AR. Nonarteritic ischemic optic neuropathy developing soon after use of sildenafil (Viagra): a report of seven new cases. J Neuroophthalmol 2005; 25:9-13.
36. Sadun AA. Metabolic optic neuropathies. Semin Ophthalmol 2002; 17:29-32.
37. Fivgas GD, Newman NJ. Anterior ischemic optic neuropathy following the use of a nasal decongestant. Am J Ophthalmol 1999; 127:104-106.
38. The Cuba Neuropathy Field Investigation Team. Epidemic optic neuropathy in Cuba-clinical characterization and risk factors. N Engl J Med 1995; 333:1176-1182.
39. Solberg Y, Rosner M, Belkin M. The association between cigarette smoking and ocular diseases. Surv Ophthalmol 1998; 42:535-547.
40. Rizzo JF 3rd, Andreoli CM, Rabinov JD. Use of magnetic resonance imaging to differentiate optic neuritis and nonarteritic anterior ischemic optic neuropathy. Ophthalmology 2002; 109:1679-1684.
41. The Optic Neuritis Study Group. Multiple sclerosis risk after optic neuritis: final Optic Neuritis Treatment Trial follow-up. Arch Neurol 2008; 65:727-732.
42. Ghezzi A, Martinelli V, Torri V, et al. Long-term follow-up of isolated optic neuritis: the risk of developing multiple sclerosis, its outcome, and the prognostic role of paraclinical tests. J Neurol 1999; 246:770-775.
43. Brex PA, Ciccarelli O, O'Riordan JI, Sailer M, Thompson AJ, Miller DH. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 2002; 346:158-164.
44. Tintore M, Rovira A, Rio J, et al. Baseline MRI predicts future attacks and disability in clinically isolated syndromes. Neurology 2006; 67:968-972.
45. Söderström M, Ya-Ping J, Hillert J. Optic neuritis: prognosis for multiple sclerosis from MRI, CSF, and HLA findings. Neurology 1998; 50:708-714.
46. Frederiksen JL, Madsen HO, Ryder LP, Larsson HB, Morling N, Svejgaard A. HLA typing in acute optic neuritis: relation to multiple sclerosis and magnetic resonance imaging findings. Arch Neurol 1997; 54:76-80.
47. Frederiksen JL, Larsson HB, Oleson J. Correlation of magnetic resonance imaging and CSF findings in patients with acute monosymptomatic optic neuritis. Acta Neurol Scand 1992; 86:317-322.
48. Beck RW, Cleary PA, Anderson MM Jr, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med 1992; 326:581-588.
49. Beck RW, Trobe JD, Moke PS, et al. Highand low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: experience of the optic neuritis treatment trial. Arch Ophthalmol 2003; 121:944-949.
50. Sellebjerg F, Nielsen HS, Frederiksen JL, Olesen J. A randomized, controlled trial of oral high-dose methylprednisolone in acute optic neuritis. Neurology 1999; 52:1479-1484.
51. Noseworthy JH, O'Brien PC, Peterson TM, et al. A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis. Neurology 2001; 56:1514-1522.
52. Roed HG, Langkilde A, Sellebjerg F, et al. A double-blind, randomized trial of IV immunoglobulin treatment in acute optic neuritis. Neurology 2005; 64:804-810.
53. Ruprecht K, Klinker E, Dintelmann T, Rieckmann P, Gold R. Plasma exchange for severe optic neuritis: treatment of 10 patients. Neurology 2004; 63:1081-1083.
54. CHAMPS Study Group. Interferon beta-1a for optic neuritis patients at high risk for multiple sclerosis. Am J Ophthalmol 2001; 132:463-471.
55. Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001; 357:1576-1582.
56. Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006; 67:1242-1249.
57. Kappos L, Freedman MS, Polman CH, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 2007; 370:389-397.
58. Lucchinetti CF, Kiers L, O'Duffy A, et al. Risk factors for developing multiple sclerosis after childhood optic neuritis. Neurology 1997; 49:1413-1418.
59. Wilejto M, Shroff M, Buncic JR, Kennedy J, Goia C, Banwell B. The clinical features, MRI findings, and outcome of optic neuritis in children. Neurology 2006; 67:258-262.